Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial
暂无分享,去创建一个
[1] Elizabeth Morris,et al. Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease , 2019, JAMA internal medicine.
[2] S. Asgary,et al. Effect of resveratrol on metabolic syndrome components: A systematic review and meta-analysis , 2019, Reviews in Endocrine and Metabolic Disorders.
[3] Andrew A. Li,et al. Potential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLD , 2018, Diseases.
[4] M. F. Polat,et al. The effect of Ramadan fasting on sirtuin and visfatin levels. , 2016, Interventional medicine & applied science.
[5] S. Hamilton-Dutoit,et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease , 2016, Scandinavian journal of gastroenterology.
[6] A. Lenzi,et al. Plasma levels of SIRT1 associate with non-alcoholic fatty liver disease in obese patients , 2015, Endocrine.
[7] A. Hekmatdoost,et al. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study , 2015, British Journal of Nutrition.
[8] Yu Qin,et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[9] K. Klein,et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[10] Yu Wang. Molecular Links between Caloric Restriction and Sir2/SIRT1 Activation , 2014, Diabetes & metabolism journal.
[11] A. Hekmatdoost,et al. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. , 2014, Nutrition research.
[12] H. A-Kader,et al. Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. , 2014, World journal of gastroenterology.
[13] H. Mutlu,et al. A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators. , 2014, Journal of gastrointestinal and liver diseases : JGLD.
[14] L. Bujanda,et al. TOPIC HIGHLIGHT , 2014 .
[15] Yong-hui Shi,et al. Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity. , 2014, Food & function.
[16] H. Grønbæk,et al. Effects of resveratrol in experimental and clinical non-alcoholic fatty liver disease. , 2014, World journal of hepatology.
[17] Byung-Hoon Lee,et al. Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase , 2014, Archives of Pharmacal Research.
[18] A. Hekmatdoost,et al. How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease? , 2013, Hepatitis monthly.
[19] J. Wylie-Rosett,et al. Nutritional Management of Insulin Resistance in Nonalcoholic Fatty Liver Disease (NAFLD) , 2013, Nutrients.
[20] K. Lankarani. Liver Transplantation for Quality as well as Quantity of Life , 2013, Hepatitis monthly.
[21] L. Guarente. Calorie restriction and sirtuins revisited , 2013, Genes & development.
[22] E. Ravussin,et al. Resveratrol vs. calorie restriction: Data from rodents to humans , 2013, Experimental Gerontology.
[23] E. Martínez-Abundis,et al. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. , 2013, Metabolic syndrome and related disorders.
[24] J. Bhatt,et al. RESVERATROL SUPPLEMENTATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PROSPECTIVE, OPEN LABEL, RANDOMIZED CONTROLLED TRIAL , 2013 .
[25] T. Netticadan,et al. Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients , 2013, Evidence-based complementary and alternative medicine : eCAM.
[26] P. Schrauwen,et al. Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits? , 2013, Annals of the New York Academy of Sciences.
[27] Nima Zamiri,et al. Non Alcoholic Fatty Liver Disease in Southern Iran: A Population Based Study , 2013, Hepatitis monthly.
[28] K. Schechtman,et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. , 2012, Cell metabolism.
[29] Alexander S. Banks,et al. Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. , 2012, Physiological reviews.
[30] J. Bhatt,et al. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. , 2012, Nutrition research.
[31] K. Cusi,et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.
[32] K. Cusi,et al. Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.
[33] R. de Cabo,et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. , 2012, Cell metabolism.
[34] N. Chalasani,et al. Dyslipidemia in Patients with Nonalcoholic Fatty Liver Disease , 2012, Seminars in Liver Disease.
[35] M. Ebrahimi-Mameghani,et al. Lifestyle Modification through Dietary Intervention: Health Promotion of Patients with Non-Alcoholic Fatty Liver Disease. , 2011, Health promotion perspectives.
[36] K. Lindor,et al. Current therapies for nonalcoholic fatty liver disease. , 2011, Drugs of today.
[37] J. Auwerx,et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. , 2011, Cell metabolism.
[38] E. Mervaala,et al. Distinct Effects of Calorie Restriction and Resveratrol on Diet-Induced Obesity and Fatty Liver Formation , 2011, Journal of nutrition and metabolism.
[39] B. Sümegi,et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. , 2011, The British journal of nutrition.
[40] T. Gotow,et al. Closer association of mitochondria with lipid droplets in hepatocytes and activation of Kupffer cells in resveratrol-treated senescence-accelerated mice , 2011, Histochemistry and Cell Biology.
[41] A. Baranova,et al. Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.
[42] F. Milagro,et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress , 2011, British Journal of Nutrition.
[43] Soyoung Kim,et al. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. , 2011, Biochemical pharmacology.
[44] H. Lang,et al. Weight loss increased serum adiponectin but decreased lipid levels in obese subjects whose body mass index was lower than 30 kg/m². , 2011, Nutrition research.
[45] E. Şenateş,et al. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease , 2011, Medical science monitor : international medical journal of experimental and clinical research.
[46] T. Szkudelski,et al. Anti‐diabetic effects of resveratrol , 2011, Annals of the New York Academy of Sciences.
[47] G. Kelly. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2. , 2010, Alternative medicine review : a journal of clinical therapeutic.
[48] Hongwei Yao,et al. Regulation of SIRT1 in cellular functions: role of polyphenols. , 2010, Archives of biochemistry and biophysics.
[49] G. Kelly. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1. , 2010, Alternative medicine review : a journal of clinical therapeutic.
[50] S. Fulda,et al. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. , 2010, The American journal of clinical nutrition.
[51] J. Baur. Resveratrol, sirtuins, and the promise of a DR mimetic , 2010, Mechanisms of Ageing and Development.
[52] E. Jackvony,et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.
[53] F. Aujard,et al. Resveratrol activates energy metabolism by influencing body temperature, locomotor activity and resting metabolic rate in a non-human primate , 2009 .
[54] A. Zarzuelo,et al. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. , 2009, Biochemical pharmacology.
[55] Min You,et al. Resveratrol alleviates alcoholic fatty liver in mice. , 2008, American journal of physiology. Gastrointestinal and liver physiology.
[56] Wei-jian Jiang. Sirtuins: novel targets for metabolic disease in drug development. , 2008, Biochemical and biophysical research communications.
[57] Z. Younossi,et al. Review article: current management of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis , 2008, Alimentary pharmacology & therapeutics.
[58] D. Allison,et al. A Low Dose of Dietary Resveratrol Partially Mimics Caloric Restriction and Retards Aging Parameters in Mice , 2008, PloS one.
[59] Lulu Chen,et al. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase , 2008, Acta Pharmacologica Sinica.
[60] C. Day,et al. Benefits of lifestyle modification in NAFLD , 2007, Gut.
[61] Lulu Chen,et al. [Effects of calorie restriction on SIRT1 expression in liver of nonalcoholic fatty liver disease: experiment with rats]. , 2007, Zhonghua yi xue za zhi.
[62] M. Kaito,et al. Restriction of dietary calories, fat and iron improves non‐alcoholic fatty liver disease , 2007, Journal of gastroenterology and hepatology.
[63] Eric Ravussin,et al. Calorie Restriction Increases Muscle Mitochondrial Biogenesis in Healthy Humans , 2007, PLoS medicine.
[64] J. Auwerx,et al. Sirtuins: The ‘magnificent seven’, function, metabolism and longevity , 2007, Annals of medicine.
[65] P. Puigserver,et al. Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α , 2006, Cell.
[66] P. Puigserver,et al. Resveratrol improves health and survival of mice on a high-calorie diet , 2006, Nature.
[67] M. Holmqvist,et al. Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.
[68] Jimmy D Bell,et al. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. , 2006, World journal of gastroenterology.
[69] Jeanne M Clark,et al. Weight Loss as a Treatment for Nonalcoholic Fatty Liver Disease , 2006, Journal of clinical gastroenterology.
[70] H. Conjeevaram,et al. One-Year Intense Nutritional Counseling Results in Histological Improvement in Patients with Nonalcoholic Steatohepatitis: A Pilot Study , 2005, The American Journal of Gastroenterology.
[71] Myriam Gorospe,et al. Calorie Restriction Promotes Mammalian Cell Survival by Inducing the SIRT1 Deacetylase , 2004, Science.
[72] Phuong Chung,et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan , 2003, Nature.
[73] A. Häkkinen,et al. Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. , 2003, Diabetes.
[74] D. Purdie,et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C , 2002, Gut.
[75] R. Levy,et al. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.
[76] Kang-Yu Peng,et al. Resveratrol exerts anti-obesity effects in high-fat diet obese mice and displays differential dosage effects on cytotoxicity, differentiation, and lipolysis in 3T3-L1 cells. , 2016, Endocrine journal.
[77] H. Poustchi,et al. Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. , 2015, World journal of hepatology.
[78] Chwan-Li Shen,et al. Novel insights of dietary polyphenols and obesity. , 2014, The Journal of nutritional biochemistry.
[79] M. Tsai,et al. Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. , 2014, Molecular nutrition & food research.
[80] N. Møller,et al. High-Dose Resveratrol Supplementation in Obese Men An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition , 2013 .
[81] M. Jafarabadi,et al. The Iranian Version of International Physical Activity Questionnaire (IPAQ) in Iran: Content and Construct Validity, Factor Structure, Internal Consistency and Stability , 2012 .